Primary Hyperoxaluria Type 1 (PH1)
Primary Hyperoxaluria Type 1 (PH1) is a rare metabolic disorder caused by mutations in the alanine glyoxylate aminotransferase (AGXT) gene that result in a deficiency of liver-specific peroxisomal alanine glyoxylate aminotransferase (AGT) and consequent overproduction of oxalate by the liver. When the kidneys can no longer clear excess oxalate, calcium oxalate (CaOx) crystals deposit in other tissues, leading to systemic oxalosis.
Resources
Leaflet
Therapies
OXLUMO® (lumasiran)
Explore clinical and educational resources related to the use of vutrisiran in adult patients with polyneuropathy of ATTRv (also known as hATTR) amyloidosis or with cardiomyopathy of wild-type or ATTRv amyloidosis.
Congresses
Publications
Primary Hyperoxaluria Type 1 (PH1)
Efficacy and Safety of Lumasiran for Advanced Primary Hyperoxaluria Type 1: 24-Month Follow-Up of the Phase 3 Illuminate-C Trial
American Journal of Kidney Diseases
